MTOR and diabetic retinopathy: Formononetin has been reported to prevent retinal apoptosis via PI3K/AKT/mTOR activation and oxidative stress/NF-κB inhibition, offering therapeutic potential for diabetic retinopathy (Li et al., 2023).